ERIS-ErisLifesciencesLtd

Research

Eris | Power of Empathy Eris Lifesciences Ltd. Live Share Price Today, Stock Analysis and Scores, Ratings, Estimates, Financials

[!info]- ERIS.NS Name: Eris Lifesciences Limited Currency: INR Volume: 76,848 Market cap: 123.581B Day range: 897 – 922.1 52W range: 551.3 – 971.9

Fri Dec 29 2023 01:54:18 GMT+0530 (India Standard Time)

Strength

Buying up brands from biocon.
matching sales estimates and growing

Products

Eris Lifesciences Ltd. is a pharmaceutical company that develops, manufactures, and sells medicines that treat both long-term and short-term illnesses 1. The company’s product portfolio includes tablets, capsules, sprays, syrups, drops, powder, injections, cookies, ointments, and soft gels to treat pain, diabetes, cardiovascular, gynecological, respiratory, neurological, and gastrointestinal disorders 2. They also sell nutrition formulations, vitamins, and minerals 2. Some of their leading brands include Glimisave, Tendia, Cyblex, Eritel, Olmin, and LNBloc 3.

Sectors

Eris Lifesciences Ltd. operates in the Pharmaceuticals sector, with a focus on chronic and acute therapy segments 4. The company provides a wide range of products in chronic and acute therapy segments which includes capsules, tablets, and sachets 5. They have established a leading presence in their core cardio-metabolic franchise 6.

Management

The management team of Eris Lifesciences Ltd. includes Mr. Amit Bakshi (Chairperson & Managing Director), Mr. Inderjeet Singh Negi (Executive Director), Ms. Kalpana Unadkat (Independent Director), Mr. Kaushal Shah (Executive Director), Mr. Krishnakumar Vaidyanathan (COO & Executive Director), Mr. Milind Talegaonkar (Co. Secretary & Compl. Officer), Mr. Prashant Gupta (Independent Director), Mr. Rajeev Dalal (Independent Director), Mr. Sachin Shah (Chief Financial Officer), and Mr. Vasudevan Sujesh (Independent Director)7.

Capacity

Eris Lifesciences Ltd. operates with over 4000 employees working out of their corporate offices in Ahmedabad and Mumbai, the field, and their Guwahati facility 8. The manufacturing plant can operate up to a maximum of three shifts per day 9.

Growth

Eris Lifesciences Ltd. has shown significant growth in recent years. The company reported that their revenue for the third quarter of FY23 climbed by 27 percent year-on-year (YoY) to a total of Rs 420 crore 1. The company has built multiple levers for growth in the branded generics space by broadening its dermatology portfolio through acquisitions, adding Insulin and its analogs in the anti-diabetes segment, maintaining an uptick in DPP4/SGLT2 sales, leveraging patient care platform and specialist engagement, and adding medical representatives to increase reach 1.

Acquisition into the nephro space by buying out business units from Biocon

Challenges

In the wake of the global pandemic, Eris was faced with 2 primary challenges: ensuring the safety of its employees, customers, and vendors as well as ensuring continuity of business to serve doctors and patients 10. The company also faces challenges due to increasing competition in the pharmaceutical industry 11.